Skip to main content

Advertisement

SpringerLink
Log in

Critical limb ischemia

  • WARD MEDICINE
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

Abstract

Critical limb ischemia (CLI) represents the most advanced clinical stage of peripheral arterial disease. It is usually caused by obstructive atherosclerotic arterial disease and is associated with very high morbidity and mortality. The pathophysiology of CLI is a complex and chronic process affecting the macrovascular and microvascular circulation of the muscle and non-muscle tissues of the lower limbs. In particular, the atherosclerosis-related vascular remodelling, angiogenesis and arteriogenesis are central phenomena in the process. The most common clinical manifestations of CLI are limb pain at rest, with or without trophic skin changes or tissue loss. Diagnosis of CLI is based on physical examination, ankle-brachial index measurement, duplex-ultrasound and angiography; transcutaneous oxygen may also help. Risk factor control is recommended for all patients with CLI. Individuals with minimal or no skin breakdown or in whom comorbid conditions avoid revascularization can be treated with medical therapy (antiplatelet agents, intravenous prostanoids, rheologic agents). Treatment of infection is mandatory to decrease the metabolic demands that hamper wound healing. Therapeutic angiogenesis has been pursued with several approaches ranging from gene therapy to the use of bone marrow-derived progenitor cells, but further phase II and III trials are needed. Finally, the evaluation of the risk, benefit and optimal timing of revascularization lesions or the decision about amputation and its extension is a complex decision that requires a multidisciplinary approach.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hirsch AT, Haskal ZJ, Hertzer NR, et al. (2006) ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 113:e463-654

    Google Scholar 

  2. Gresele P, Migliacci R (2009) The peripheral arterial disease subgroup in the CHARISMA trial: does it tell us anything new? Eur Heart J 30:131–132

    Article  PubMed  Google Scholar 

  3. Norgren L, Hyatt WR, Dormandy JA et al (2007) Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 33:S1–S75

    Article  PubMed  Google Scholar 

  4. Busti C, Falcinelli E, Momi S, Gresele P (2010) Matrix metalloproteinases and peripheral arterial disease. Intern Emerg Med 5:13–25

    Article  PubMed  Google Scholar 

  5. Gresele P, Momi S, Migliacci R (2010) Endothelium, venous thromboembolism and ischaemic cardiovascular events. Thromb Haemost 103:56–61

    Article  PubMed  CAS  Google Scholar 

  6. Gresele P, Migliacci R, Procacci A, De Monte P, Bonizzoni E (2007) Prevention by NCX 4016, a nitric oxide-donating aspirin, but not by aspirin, of the acute endothelial dysfunction induced by exercise in patients with intermittent claudication. Thromb Haemost 97:444–450

    PubMed  CAS  Google Scholar 

  7. Migliacci R, Nasorri R, Ricciarini P, Gresele P (2008) Ankle-brachial index measured by palpation for the diagnosis of peripheral arterial disease. Fam Pract 25:228–232

    Article  PubMed  Google Scholar 

  8. Ruangsetakit C, Chinsakchai K, Mahawongkajit P, Wongwanit C, Mutirangura P (2010) Transcutaneous oxygen tension: a useful predictor of ulcer healing in critical limb ischaemia. J Wound Care 19:202–206

    PubMed  CAS  Google Scholar 

  9. Annex BH (2007) Is a simple biomarker for peripheral arterial disease on the horizon? Circulation 116:1346–1348

    Article  PubMed  Google Scholar 

  10. Wilson AM, Kimura E, Harada RK et al (2007) B2-Microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies. Circulation 116:1396–1403

    Article  PubMed  CAS  Google Scholar 

  11. Busti C, Migliacci R, Falcinelli E, Gresele P (2009) Plasma levels of beta(2)-microglobulin, a biomarker of peripheral arterial disease, are not affected by maximal leg exercise in patients with intermittent claudication. Atherosclerosis 203:38–40

    Article  PubMed  CAS  Google Scholar 

  12. Falcinelli E, Pompili M, Appolloni V, Pengo V, Gresele P (2010) Plasma matrix metalloproteinase (MMP)-2 as a marker of arterial thrombosis in patients with primary antiphospholipid syndrome. Blood Transfus 8:OC081

    Google Scholar 

  13. Tayebjee MH, Tan KT, MacFadyen RJ et al (2005) Abnormal circulating levels of metalloprotease 9 and its tissue inhibitor 1 in angiographically proven peripheral arterial disease: relationship to disease severity. J Intern Med 257:110–116

    Article  PubMed  CAS  Google Scholar 

  14. Sartori M, Favaretto E, Legnani C (2010) Thrombophilic risk factors and peripheral arterial disease severity. Thromb Haemost 104:71–77

    Article  PubMed  CAS  Google Scholar 

  15. Davì G, Gresele P, Violi F et al (1997) Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation 96:69–75

    PubMed  Google Scholar 

  16. Gresele P, Catalano M, Giammarresi C et al (1997) Platelet activation markers in patients with peripheral arterial disease–a prospective comparison of different platelet function tests. Thromb Haemost 78:1434–1437

    PubMed  CAS  Google Scholar 

  17. Lessiani G, Vazzana N, Cuccurullo C et al (2011) Inflammation, oxidative stress and platelet activation in aspirin-treated critical limb ischaemia: beneficial effects of iloprost. Thromb Haemost 105:321–328

    Article  PubMed  CAS  Google Scholar 

  18. Gresele P, Momi S, Falcinelli E. (2011) Anti-platelet therapy: Phosphodiesterase inhibitors. Br J Clin Pharmacol. [Epub ahead of print]

  19. Miyashita Y, Saito S, Miyamoto A, Iida O, Nanto S (2011) Cilostazol increases skin perfusion pressure in severely ischemic limbs. Angiology 62:15–17

    Article  PubMed  Google Scholar 

  20. Varu VN, Hogg ME, Kibbe MR (2010) Critical limb ischemia. J Vasc Surg. 51:230–241

    Article  PubMed  Google Scholar 

  21. Dattilo PB, Casserly IP (2011) Critical limb ischemia: endovascular strategies for limb salvage. Prog Cardiovasc Dis 54:47–60

    Article  PubMed  Google Scholar 

  22. McCann AB, Jaff MR (2009) Treatment strategies for peripheral artery disease. Expert Opin Pharmacother 10:1571–1586

    Article  PubMed  CAS  Google Scholar 

  23. Tongers J, Roncalli JG, Losordo DW (2008) Therapeutic angiogenesis for critical limb ischemia: microvascular therapies coming of age. Circulation 118:9–16

    Article  PubMed  Google Scholar 

  24. Fadini GP, Agostini C, Avogaro A (2010) Autologous stem cell therapy for peripheral arterial disease meta-analysis and systematic review of the literature. Atherosclerosis 209:10–17

    Article  PubMed  CAS  Google Scholar 

  25. Lawall H, Bramlage P, Amann B (2011) Treatment of peripheral arterial disease using stem and progenitor cell therapy. J Vasc Surg 53:445–453

    Google Scholar 

  26. Amann B, Ludemann C, Ruckert R et al (2008) Design and rationale of a randomized, double-blind, placebo-controlled phase III study for autologous bone marrow cell transplantation in critical limb ischemia: the BONe Marrow Outcomes Trial in Critical Limb Ischemia (BONMOT-CLI). Vasa 37:319–325

    Google Scholar 

  27. Belch J, Hiatt WR, Baumgartner I, Driver IV, Nikol S, Norgren L, Van Belle E, TAMARIS Committees and Investigators (2011) Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet 377:1929–1937

    Google Scholar 

  28. Ho TK, Abraham DJ, Black CM et al (2006) Hypoxia-inducible factor 1 in lower limb ischemia. Vascular 14:321–327

    Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Dipartimento di Medicina Interna, Sezione di Medicina Interna e Cardiovascolare, Università di Perugia, Via E. dal Pozzo, Perugia, 06126, Italy

    Paolo Gresele, Chiara Busti & Tiziana Fierro

Authors
  1. Paolo Gresele
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chiara Busti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tiziana Fierro
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paolo Gresele.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gresele, P., Busti, C. & Fierro, T. Critical limb ischemia. Intern Emerg Med 6 (Suppl 1), 129 (2011). https://doi.org/10.1007/s11739-011-0683-7

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11739-011-0683-7

Keywords

Search

Navigation